AbbVie Inc.’s JAK1 inhibitor Rinvoq (upadacitinib) has a decent shot at US Food and Drug Administration approval in ulcerative colitis (UC) based on positive data from its Phase III studies. The last of three pivotal trials for the indication showed strong efficacy, but also a low incidence of adverse events that have previously drawn regulatory concern, which could feed into lingering worries about the safety of the JAK class.
The drug maker announced results of the study on 29 June, saying that the study met its primary and secondary...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
